Sanofi's Lantus insulin favored over rival: study
LONDON (Reuters) - A once-daily injection of Sanofi-Aventis's insulin drug Lantus controls blood sugar as effectively as Eli Lilly's Humalog, which needs to be taken three times daily, researchers said on Friday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=0oxfTM" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=0oxfTM)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=b52MKPF" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=b52MKPF) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=IdSopzf" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=IdSopzf) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=jOTtVCf" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=jOTtVCf)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/259341645" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/259341645/idUSL2777885820080328